<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xml:lang="en" article-type="research-article" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">OR</journal-id>
<journal-title-group>
<journal-title>Oncology Reports</journal-title>
</journal-title-group>
<issn pub-type="ppub">1021-335X</issn>
<issn pub-type="epub">1791-2431</issn>
<publisher>
<publisher-name>D.A. Spandidos</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3892/or.2018.6358</article-id>
<article-id pub-id-type="publisher-id">or-39-06-3055</article-id>
<article-categories>
<subj-group>
<subject>Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Huaier suppresses proliferative and metastatic potential of prostate cancer PC3 cells via downregulation of Lamin B1 and induction of autophagy</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author"><name><surname>Yang</surname><given-names>Ailin</given-names></name>
<xref rid="af1-or-39-06-3055" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author"><name><surname>Zhao</surname><given-names>Yanan</given-names></name>
<xref rid="af1-or-39-06-3055" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author"><name><surname>Wang</surname><given-names>Ying</given-names></name>
<xref rid="af2-or-39-06-3055" ref-type="aff">2</xref></contrib>
<contrib contrib-type="author"><name><surname>Zha</surname><given-names>Xiaojun</given-names></name>
<xref rid="af3-or-39-06-3055" ref-type="aff">3</xref></contrib>
<contrib contrib-type="author"><name><surname>Zhao</surname><given-names>Yunfang</given-names></name>
<xref rid="af1-or-39-06-3055" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author"><name><surname>Tu</surname><given-names>Pengfei</given-names></name>
<xref rid="af1-or-39-06-3055" ref-type="aff">1</xref>
<xref rid="c1-or-39-06-3055" ref-type="corresp"/></contrib>
<contrib contrib-type="author"><name><surname>Hu</surname><given-names>Zhongdong</given-names></name>
<xref rid="af1-or-39-06-3055" ref-type="aff">1</xref>
<xref rid="c1-or-39-06-3055" ref-type="corresp"/></contrib>
</contrib-group>
<aff id="af1-or-39-06-3055"><label>1</label>Modern Research Center for Traditional Chinese Medicine, School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 100029, P.R. China</aff>
<aff id="af2-or-39-06-3055"><label>2</label>Department of Molecular Orthopaedics, Beijing Institute of Traumatology and Orthopaedics, Beijing Jishuitan Hospital, Beijing 100035, P.R. China</aff>
<aff id="af3-or-39-06-3055"><label>3</label>Department of Biochemistry and Molecular Biology, School of Basic Medicine, Anhui Medical University, Hefei, Anhui 230032, P.R. China</aff>
<author-notes>
<corresp id="c1-or-39-06-3055"><italic>Correspondence to</italic>: Dr Zhongdong Hu or Professor Pengfei Tu, Modern Research Center for Traditional Chinese Medicine, School of Chinese Materia Medica, Beijing University of Chinese Medicine, 11 North Third Ring Road, Chaoyang, Beijing 100029, P.R. China, E-mail: <email>zdhu@bucm.edu.cn</email>, E-mail: <email>pengfeitu@163.com</email></corresp>
</author-notes>
<pub-date pub-type="ppub"><month>06</month><year>2018</year></pub-date>
<pub-date pub-type="epub"><day>05</day><month>04</month><year>2018</year></pub-date>
<volume>39</volume>
<issue>6</issue>
<fpage>3055</fpage>
<lpage>3063</lpage>
<history>
<date date-type="received"><day>24</day><month>04</month><year>2017</year></date>
<date date-type="accepted"><day>01</day><month>04</month><year>2018</year></date>
</history>
<permissions>
<copyright-statement>Copyright &#x00A9; 2018, Spandidos Publications</copyright-statement>
<copyright-year>2018</copyright-year>
</permissions>
<abstract>
<p>Prostate cancer is one of the most common malignancies occurring in males. Although large advances have been made in the pathogenesis of prostate cancer, the development of drugs with high efficacy and low toxicity for the treatment of prostate cancer is urgently needed. Recently, more and more attention has been paid to the antitumor effect of Traditional Chinese Medicine (TCM) worldwide. <italic>Trametes robiniophila</italic> Murr. (Huaier) has been applied as a type of TCM drug for ~1,600 years. Huaier exhibits excellent clinical efficacy in the treatment of cancer, including prostate cancer. However, the mechanisms underlying the anti-prostate cancer effect of Huaier remain largely unclear. In the present study, we revealed that Huaier aqueous extract inhibited the proliferative and metastatic capabilities of human prostate cancer PC3 cells through CCK-8 assay, <italic>in vitro</italic> scratch assay and Transwell assay. Moreover, decreased Lamin B1 was implicated in Huaier-induced suppression of proliferative and metastatic potential of PC3 cells. Intriguingly, we demonstrated that Huaier treatment induced autophagic cell death in PC3 cells. This study sheds new light on the mechanisms underlying the activity of Huaier against prostate cancer and provides a new theoretical basis for the clinical application of Huaier in prostate cancer.</p>
</abstract>
<kwd-group>
<kwd>&#x03A4;raditional Chinese &#x039C;edicine</kwd>
<kwd>Huaier</kwd>
<kwd>prostate cancer</kwd>
<kwd>Lamin B1</kwd>
<kwd>autophagy</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec sec-type="intro">
<title>Introduction</title>
<p>Prostate cancer is one of the leading causes of cancer-related death in men worldwide. At present, treatment approaches for prostate cancer mainly include surgery, chemotherapy and hormonal therapy (<xref rid="b1-or-39-06-3055" ref-type="bibr">1</xref>,<xref rid="b2-or-39-06-3055" ref-type="bibr">2</xref>). The selection of the treatment method for prostate cancer generally depends on the clinical stage, Gleason score, age of patients, and other factors. To date, the chemotherapeutic effect for prostate cancer is limited due to drug resistance and cytotoxicity (<xref rid="b3-or-39-06-3055" ref-type="bibr">3</xref>&#x2013;<xref rid="b5-or-39-06-3055" ref-type="bibr">5</xref>), which makes it urgent to develop new therapeutic drugs to further improve the clinical outcomes of patients with prostate cancer.</p>
<p>Recently, increased attention has been paid to the anticancer effects of Traditional Chinese Medicine (TCM) largely due to the advantages of low toxicity and multi-targets (<xref rid="b6-or-39-06-3055" ref-type="bibr">6</xref>&#x2013;<xref rid="b8-or-39-06-3055" ref-type="bibr">8</xref>). <italic>Trametes robiniophila</italic> Murr. (Huaier) has a long history of disease treatment for more than 1,600 years in China. Numerous studies have revealed that Huaier exhibits superior effects for the treatment of several types of cancers, such as hepatocellular carcinoma, breast, ovarian, lung and prostate cancer (<xref rid="b9-or-39-06-3055" ref-type="bibr">9</xref>&#x2013;<xref rid="b14-or-39-06-3055" ref-type="bibr">14</xref>). The underlying mechanisms of the anticancer effects of Huaier include the inhibition of tumor cell proliferation, metastasis and angiogenesis, as well as induction of apoptosis (<xref rid="b11-or-39-06-3055" ref-type="bibr">11</xref>,<xref rid="b13-or-39-06-3055" ref-type="bibr">13</xref>,<xref rid="b15-or-39-06-3055" ref-type="bibr">15</xref>&#x2013;<xref rid="b17-or-39-06-3055" ref-type="bibr">17</xref>). However, the mechanisms underlying the anti-prostate cancer effect of Huaier remain to be elucidated.</p>
<p>In the present study, we demonstrated that Huaier significantly inhibited the proliferative and metastatic potential of human prostate cancer PC3 cells. Moreover, downregulation of Lamin B1 was responsible for the inhibition of the proliferative and metastatic capacity of PC3 cells exposed to Huaier aqueous extract. More importantly, Huaier treatment activated autophagy in PC3 cells, and suppression of autophagy attenuated Huaier-induced cell death in PC3 cells. Thus, the present study provides a theoretical and experimental basis for the clinical application of Huaier for the treatment of prostate cancer.</p>
</sec>
<sec sec-type="materials|methods">
<title>Materials and methods</title>
<sec>
<title/>
<sec>
<title>Reagents and antibodies</title>
<p>Ham&#x0027;s F-12K (Kaighn&#x0027;s) medium, fetal bovine serum (FBS), penicillin-streptomycin solution, 0.25&#x0025; trypsin, Matrigel and Transwell chambers were purchased from Corning Life Sciences (Corning, NY, USA). Cell Counting Kit-8 (CCK-8) was obtained from Dojindo Laboratories (Kumamoto, Japan). 3-Methyladenine (3-MA) was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Bafilomycin A1 was obtained from Aladdin Shanghai Biochemical Technology Co., Ltd. (Shanghai, China). Bis-Tris Nu-PAGE gels (4&#x2013;12&#x0025;) were obtained from Invitrogen (Thermo Fisher Scientific, Inc., Waltham, MA, USA). Super ECL Plus was from GE Healthcare (Pittsburgh, PA, USA). &#x03B2;-actin antibody was purchased from Abgent (cat. no. AM1829b; San Diego, CA, USA). Atg3 (cat. no. 3415), Beclin-1 (cat. no. 3495) and Atg5 (cat. no. 12994) antibodies were purchased from Cell Signaling Technology (Danvers, MA, USA). LC3 antibody was from MBL (cat. no. PM036; Tokyo, Japan). Lamin B1 (cat. no. sc-20682), HRP-labeled goat anti-mouse (cat. no. sc-2005) and goat anti-rabbit (cat. no. sc-2004) antibodies were from Santa Cruz Biotechnology.</p>
</sec>
<sec>
<title>Preparation of Huaier aqueous extract</title>
<p>The electuary ointment of Huaier was obtained from Gaitianli Medicine Co., Ltd. (Jiangsu, China). It was dissolved in F-12K complete medium to obtain a 10 mg/ml stock solution and was stored at 4&#x00B0;C after sterilization by filtration.</p>
</sec>
<sec>
<title>Cell culture</title>
<p>Human prostate cancer PC3 cells were obtained from the Cell Culture Center of the Institute of Basic Medical Sciences of the Chinese Academy of Medical Sciences (Beijing, China). PC3 cells were maintained in Ham&#x0027;s F-12K (Kaighn&#x0027;s) medium containing 10&#x0025; FBS and 1&#x0025; penicillin/streptomycin at 37&#x00B0;C and 5&#x0025; CO<sub>2</sub>.</p>
</sec>
<sec>
<title>Cell viability assay</title>
<p>PC3 cells were seeded into 96-well plates at a density of 3,500 cells/well. On the following day, the cells were treated with Huaier aqueous extract at the indicated concentrations for different times. Afterwards, 10 &#x00B5;l of CCK-8 was added into each well and incubated at 37&#x00B0;C for 2 h. The optical density (OD) was then measured at 450 nm using a microplate reader (Perkin-Elmer, Waltham, MA, USA).</p>
</sec>
<sec>
<title>In vitro scratch assay</title>
<p>The scratch assay was performed as described previously (<xref rid="b10-or-39-06-3055" ref-type="bibr">10</xref>,<xref rid="b18-or-39-06-3055" ref-type="bibr">18</xref>). In brief, PC3 cells were seeded into 12-well plates with complete medium. Cells in a subconfluent state were starved with serum-free medium for 12 h, and then a straight cell-free wound was created using a 10-&#x00B5;l pipette tip. Next, the cells were maintained in serum-free medium containing 4 mg/ml of Huaier extract. The scratch width was measured at 0 and 24 h. The cell migration distances were analyzed quantitatively.</p>
</sec>
<sec>
<title>Transwell assay</title>
<p>The Transwell system was established as previously described (<xref rid="b19-or-39-06-3055" ref-type="bibr">19</xref>,<xref rid="b20-or-39-06-3055" ref-type="bibr">20</xref>). PC3 cells (1&#x00D7;10<sup>5</sup>) were resuspended in 200 &#x00B5;l serum-free medium containing Huaier extract (4 mg/ml) and then added to the upper chamber of the Transwell system. The lower chamber was filled with 750 &#x00B5;l complete medium containing 10&#x0025; FBS. After incubation for 36 h, the cells were removed from the upper surface of the membrane with a cotton swab. Next, the cells on the bottom surface of the membrane were fixed and then stained with crystal violet. The Transwell chamber was washed twice with phosphate-buffered saline (PBS) to remove the dye. The invasive cells were observed and counted on 5 random fields under an inverted microscope (Leica Microsystems GmbH, Wetzlar, Germany).</p>
</sec>
<sec>
<title>Quantitative real-time PCR</title>
<p>Total RNA was extracted from PC3 cells using E.Z.N.A.<sup>&#x00AE;</sup> Total RNA Kit I (Omega Bio-tek, Inc., Norcross, GA, USA) and reverse-transcribed into cDNA using the PrimeScript RT reagent kit (Takara Biotechnology, Inc., Dalian, China) according to the manufacturer&#x0027;s protocols. cDNA was used as a template for the quantitative PCR using the TransStart Top Green qPCR SuperMix (Beijing TransGen Biotech Co., Ltd., Beijing, China). The primer sequences were: human <italic>Lamin B1</italic> forward, 5&#x2032;-TTCTCGAAGCTTGATCTGGG-3&#x2032; and human <italic>Lamin B1</italic> reverse, 5&#x2032;-GATCGAGCTGGGCAAGTG-3&#x2032;; human &#x03B2;-<italic>actin</italic> forward, 5&#x2032;-GTTGTCGACGACGAGCG-3&#x2032; and human &#x03B2;-<italic>actin</italic> reverse, 5&#x2032;-GCACAGAGCCTCGCCTT-3&#x2032;.</p>
</sec>
<sec>
<title>Immunoblotting</title>
<p>Cells were washed twice with PBS and harvested with lysis buffer [10 mM Tris (pH 6.8), 2&#x0025; SDS, 10&#x0025; glycerol and 100 mM DTT], and then cell lysates were boiled for 10 min at 98&#x00B0;C. The levels of indicated proteins were detected by immunoblot analysis as previously described (<xref rid="b21-or-39-06-3055" ref-type="bibr">21</xref>).</p>
</sec>
<sec>
<title>RNA interference</title>
<p>All siRNAs were synthesized by Shanghai GenePharma Co., Ltd. (Shanghai, China). PC3 cells were seeded in 6-well plates and then transfected with siRNAs targeting Lamin B1, Atg5 or Beclin-1 using Lipofectamine 2000 (Thermo Fisher Scientific, Inc., Waltham, MA, USA) according to the manufacturer&#x0027;s instructions. The siRNA target sequences were: <italic>Lamin B1</italic> (human), 5&#x2032;-CGCGCTTGGTAGAGGTGGA-3&#x2032;; <italic>Atg5</italic> (human), 5&#x2032;-GGACGAATTCCAACTTGTT-3&#x2032;; <italic>Beclin-1</italic> (human), 5&#x2032;-CAGTTTGGCACAATCAATA-3&#x2032;; negative control (NC), 5&#x2032;-TTCTCCGAACGTGTCACGT-3&#x2032;.</p>
</sec>
<sec>
<title>Electron microscopy</title>
<p>Cells were collected with 2.5&#x0025; glutaraldehyde, and then centrifuged (1,000 revolutions, 10 min) and washed twice with PBS. The samples were post-fixed with 1&#x0025; osmium tetroxide at 4&#x00B0;C for 2 h in the dark and then washed three times with 0.1MPB. After dehydration, the permeation, paraffin embedding and section staining were performed as previously described (<xref rid="b22-or-39-06-3055" ref-type="bibr">22</xref>). The ultrastructure of cells was observed under a JEM-1230 transmission electron microscope (JEOL, Ltd., Tokyo, Japan).</p>
</sec>
<sec>
<title>Acridine orange staining</title>
<p>PC3 cells treated with 8 mg/ml Huaier exact for indicated times were washed twice with PBS and stained with 10 &#x00B5;g/ml acridine orange for 20 min at 37&#x00B0;C in the dark. The cells were observed under an inverted fluorescence microscope.</p>
</sec>
<sec>
<title>Immunofluorescence assay</title>
<p>Cells seeded on confocal dishes were washed with PBS and fixed in 4&#x0025; paraformaldehyde for 10 min, and then permeabilized with PBS containing 0.5&#x0025; Triton X-100 for 20 min. Next, the cells were washed three times with PBS and blocked with 1&#x0025; BSA for 1 h at 37&#x00B0;C, and then incubated with the primary antibody (1:100) overnight at 4&#x00B0;C. Subsequently, the cells were washed with PBS and then incubated with anti-rabbit FITC-conjugated secondary antibody (1:100) for 1 h at 37&#x00B0;C. Nucleus was counterstained with DAPI in the dark after being washed with PBS. The cells were observed and photographed with a laser scanning confocal microscope (Olympus FV1000; Olympus Corp., Tokyo, Japan).</p>
</sec>
<sec>
<title>Statistical analysis</title>
<p>The data are presented as mean &#x00B1; SD of triplicate samples. The statistical analysis in this study was evaluated by the Student&#x0027;s t-test and ANOVA using GraphPad Prism 5.0 software (GraphPad Software, Inc., La Jolla, CA, USA). P&#x003C;0.05 was considered to indicate a statistically significant result.</p>
</sec>
</sec>
</sec>
<sec sec-type="results">
<title>Results</title>
<sec>
<title/>
<sec>
<title>Huaier inhibits the proliferative and metastatic potential of human prostate cancer PC3 cells</title>
<p>CCK-8 assay indicated that Huaier aqueous extract significantly inhibited proliferation of the PC3 cells in a time- and dose-dependent manner (<xref rid="f1-or-39-06-3055" ref-type="fig">Fig. 1A</xref>). The IC50 value of PC3 cells exposed to Huaier for 48 h was 8.18 mg/ml. The wound healing assay is widely used to evaluate the migratory ability of cells <italic>in vitro</italic>. As shown in <xref rid="f1-or-39-06-3055" ref-type="fig">Fig. 1B</xref>, the migration capacity of PC3 cells was decreased after treatment with Huaier, and the migration inhibition rate of PC3 cells treated with Huaier was 44.68&#x00B1;16.39&#x0025;. Moreover, the invasion capacity of cells <italic>in vitro</italic> is frequently examined by using Transwell assay. As shown in <xref rid="f1-or-39-06-3055" ref-type="fig">Fig. 1C</xref>, after treatment of PC3 cells with 4 mg/ml Huaier aqueous extract for 36 h, the number of cells that had successfully passed through the Matrigel-coated membrane was markedly reduced compared with that of the control group cells. Taken together, Huaier markedly suppressed the proliferative and metastatic capability of the human prostate cancer cells.</p>
</sec>
<sec>
<title>Huaier downregulates Lamin B1 expression in human prostate cancer PC3 cells</title>
<p>Lamin B1 is a member of the lamin family making up the nuclear matrix and is abnormally overexpressed in multiple types of cancers including prostate, hepatocellular carcinoma and pancreatic cancer (<xref rid="b19-or-39-06-3055" ref-type="bibr">19</xref>,<xref rid="b23-or-39-06-3055" ref-type="bibr">23</xref>&#x2013;<xref rid="b25-or-39-06-3055" ref-type="bibr">25</xref>). Moreover, Lamin B1 positively regulates the proliferation and invasion of pancreatic cancer cells (<xref rid="b25-or-39-06-3055" ref-type="bibr">25</xref>). Our previous study revealed that as a pro-oncogenic gene, Lamin B1 was dramatically decreased in human hepatoma SKHEP-1 cells exposed to Huaier (<xref rid="b10-or-39-06-3055" ref-type="bibr">10</xref>). Intriguingly, qRT-PCR and western blot analysis demonstrated that Huaier aqueous extract significantly inhibited the mRNA and protein levels of Lamin B1 in PC3 cells in a dose-dependent manner (<xref rid="f2-or-39-06-3055" ref-type="fig">Fig. 2A and B</xref>).</p>
</sec>
<sec>
<title>Lamin B1 is involved in the inhibition of proliferation and metastatic potential of PC3 cells exposed to Huaier</title>
<p>Next, we investigated whether downregulation of Lamin B1 contributes to Huaier-mediated inhibition of proliferative and metastatic capacity of PC3 cells by using RNA interference. Transfection with siRNAs targeting Lamin B1 markedly reduced Lamin B1 expression (<xref rid="f3-or-39-06-3055" ref-type="fig">Fig. 3A</xref>). Moreover, depletion of Lamin B1 significantly blunted the proliferation of PC3 cells (<xref rid="f3-or-39-06-3055" ref-type="fig">Fig. 3B</xref>). In addition, reduction of Lamin B1 substantially suppressed the migration and invasion of PC3 cells (<xref rid="f3-or-39-06-3055" ref-type="fig">Fig. 3C and D</xref>). Thus, Lamin B1 positively regulates the proliferation and metastatic potential of human prostate cancer PC3 cells. To further investigate the role of Lamin B1 in the inhibition of proliferative and metastatic potential of PC3 cells in the presence of Huaier, we treated PC3 cells transfected with Lamin B1 siRNAs or negative control siRNAs with Huaier aqueous extract. As depicted in <xref rid="f4-or-39-06-3055" ref-type="fig">Fig. 4A</xref>, depletion of Lamin B1 attenuated the inhibitory effect of Huaier on the proliferation of PC3 cells. Additionally, the suppression of migration and invasion of PC3 cells caused by Huaier treatment were significantly impaired by knockdown of Lamin B1 (<xref rid="f4-or-39-06-3055" ref-type="fig">Fig. 4B and C</xref>). Collectively, decreased Lamin B1 is partially responsible for the inhibition of proliferation and the metastatic potential of PC3 cells in the presence of Huaier.</p>
</sec>
<sec>
<title>Huaier induces autophagy in PC3 cells</title>
<p>Autophagy is one of the underlying mechanisms for drug-induced cell death (<xref rid="b26-or-39-06-3055" ref-type="bibr">26</xref>,<xref rid="b27-or-39-06-3055" ref-type="bibr">27</xref>). In the present study we determined the effect of Huaier on autophagy in PC3 cells. Observation of autophagosomes and other related subcellular structures in the cytoplasm with transmission electron microscope is widely used for autophagy assessment (<xref rid="b22-or-39-06-3055" ref-type="bibr">22</xref>,<xref rid="b28-or-39-06-3055" ref-type="bibr">28</xref>,<xref rid="b29-or-39-06-3055" ref-type="bibr">29</xref>). Ultrastructural changes of PC3 cells treated with Huaier were observed by transmission electron microscope. As shown in <xref rid="f5-or-39-06-3055" ref-type="fig">Fig. 5A</xref>, PC3 cells treated with Huaier exhibited typical characteristics of autophagy: autophagosomes and autolysosomes which contained cytoplasmic components. Moreover, acridine orange staining was used to observe the accumulation of autophagy vesicles. The number of acidic vesicles marked by orange fluorescence increased in response to Huaier treatment in a time-dependent manner (<xref rid="f5-or-39-06-3055" ref-type="fig">Fig. 5B</xref>). A series of autophagy-related proteins participate in different stages of autophagosome formation, such as Atg3, Atg5 and Beclin-1 (<xref rid="b30-or-39-06-3055" ref-type="bibr">30</xref>&#x2013;<xref rid="b33-or-39-06-3055" ref-type="bibr">33</xref>). LC3 is an autophagosomal marker protein (<xref rid="b34-or-39-06-3055" ref-type="bibr">34</xref>). LC3-II, one form of LC3, accumulates on the membranes of autophagosomes and is widely used as a marker for autophagy evaluation (<xref rid="b34-or-39-06-3055" ref-type="bibr">34</xref>,<xref rid="b35-or-39-06-3055" ref-type="bibr">35</xref>). Western blot analysis revealed that Huaier treatment led to increase in the expression of Atg3, Atg5, Beclin-1 and LC3-II in a dose- and time-dependent manner in PC3 cells (<xref rid="f5-or-39-06-3055" ref-type="fig">Fig. 5C and D</xref>). Moreover, Huaier treatment markedly increased LC3 puncta in number and intensity in PC3 cells under a fluorescence microscope (<xref rid="f5-or-39-06-3055" ref-type="fig">Fig. 5E</xref>), indicating that the number of autophagosomes was increased in the presence of Huaier. Taken together, Huaier evidently promoted autophagy in PC3 cells.</p>
</sec>
<sec>
<title>Autophagy inhibition attenuates Huaier-induced inhibition of proliferation of PC3 cells</title>
<p>To investigate whether autophagy was involved in the inhibition of proliferation of PC3 cells by Huaier, we suppressed autophagy with two autophagy inhibitors and RNA interference. As depicted in <xref rid="f6-or-39-06-3055" ref-type="fig">Fig. 6A and B</xref>, inhibition of autophagy with 3-MA or bafilomycin A1 significantly impaired the sensitivity of PC3 cells to Huaier treatment. Moreover, Atg5 and Beclin-1, two essential components involved in autophagosome formation (<xref rid="b36-or-39-06-3055" ref-type="bibr">36</xref>), were efficiently knocked down in the PC3 cells transfected with siRNAs (<xref rid="f6-or-39-06-3055" ref-type="fig">Fig. 6C and D</xref>). Consistent with the results of autophagy inhibitors, suppression of autophagy with siRNAs against Atg5 or Beclin-1 remarkably blunted the inhibitory effect of Huaier on the proliferation of PC3 cells (<xref rid="f6-or-39-06-3055" ref-type="fig">Fig. 6C and D</xref>). Collectively, the inhibitory proliferation of PC3 cells exposed to Huaier is partially mediated by activation of autophagy.</p>
</sec>
</sec>
</sec>
<sec sec-type="discussion">
<title>Discussion</title>
<p>In recent years, the antitumor effects of Huaier have drawn the attention of cancer researchers. Many clinical applications have demonstrated that Huaier can be used for the treatment of multiple types of cancers including prostate cancer. However, the anti-prostate cancer effect of Huaier and its underlying mechanisms remain elusive. In the present study, we demonstrated that Huaier inhibited the proliferation and metastatic potential of human prostate cancer PC3 cells partially through downregulation of Lamin B1. In addition, we revealed that Huaier treatment induced autophagic cell death in PC3 cells.</p>
<p>Uncontrolled cell proliferation is one of the hallmarks of cancer (<xref rid="b37-or-39-06-3055" ref-type="bibr">37</xref>). Inhibition of cancer cell proliferation can be used as a strategy to treat cancer. Metastasis is a complex multi-step process which plays a pivotal role in the progression of cancer (<xref rid="b38-or-39-06-3055" ref-type="bibr">38</xref>). Cancer metastasis is responsible for ~90&#x0025; of human cancer-related deaths (<xref rid="b39-or-39-06-3055" ref-type="bibr">39</xref>). Metastases to distant organs such as the bone, liver, lungs and brain frequently occur in the advanced stage of prostate cancer (<xref rid="b40-or-39-06-3055" ref-type="bibr">40</xref>,<xref rid="b41-or-39-06-3055" ref-type="bibr">41</xref>). Most prostate cancer-related deaths result from metastases. Herein we revealed that Huaier had excellent anti-proliferative and anti-metastatic effects in PC3 cells. Thus, Huaier can be used as a candidate drug for targeting the proliferation and metastasis of cancer cells in the treatment of human prostate cancer. Lamin B1 is an important member of the lamin protein family (<xref rid="b23-or-39-06-3055" ref-type="bibr">23</xref>) and was reported to be a carcinogenic gene (<xref rid="b25-or-39-06-3055" ref-type="bibr">25</xref>). The levels of Lamin B1 are elevated in tumors of patients with hepatocellular carcinoma (<xref rid="b24-or-39-06-3055" ref-type="bibr">24</xref>). Moreover, Lamin B1 expression was found to be markedly increased in malignant prostate cancer (<xref rid="b19-or-39-06-3055" ref-type="bibr">19</xref>). Knockdown of Lamin B1 expression by siRNAs induced apoptosis in HeLa cells (<xref rid="b42-or-39-06-3055" ref-type="bibr">42</xref>). Our previous study demonstrated that Lamin B1 was remarkably downregulated in human hepatoma SKHEP-1 cells exposed to Huaier (<xref rid="b10-or-39-06-3055" ref-type="bibr">10</xref>). In the present study, we revealed that Huaier treatment markedly reduced Lamin B1 expression in human prostate cancer PC3 cells. Furthermore, Lamin B1 was required for the inhibition of proliferation and metastatic potential of PC3 cells by Huaier. As an oncogenic protein, Lamin B1 is a novel target of Huaier for prostate cancer treatment.</p>
<p>Autophagy is a normal physiological process in which the cytoplasmic components including misfolded proteins and damaged organelles are surrounded to form autophagosomes that are eventually transported to lysosomes for degradation (<xref rid="b20-or-39-06-3055" ref-type="bibr">20</xref>,<xref rid="b43-or-39-06-3055" ref-type="bibr">43</xref>). As one of the underlying mechanisms of cell death, autophagy frequently occurs in cancer cells in response to antitumor therapies (<xref rid="b44-or-39-06-3055" ref-type="bibr">44</xref>&#x2013;<xref rid="b47-or-39-06-3055" ref-type="bibr">47</xref>). Huaier triggered autophagy in human breast cancer MDA-MB-231, MDA-MB-468 and MCF7 cells, and autophagy inhibition impaired Huaier-induced cell death in these cancer cells. Huaier-induced cytotoxicity in human breast cancer cells was partialy due to activation of autophagy (<xref rid="b48-or-39-06-3055" ref-type="bibr">48</xref>). In addition, Huaier augmented tamoxifen-induced autophagy in ER-positive breast cancer cells (<xref rid="b49-or-39-06-3055" ref-type="bibr">49</xref>). We demonstrated that Huaier extract dramatically triggered autophagy in PC3 cells through electron microscopy observation, acridine orange staining, western blotting and immunofluorescence assay. Moreover, inhibition of autophagy via drugs or siRNAs significantly abrogated Huaier-induced cytotoxicity in PC3 cells. Therefore, autophagic cell death is involved in Huaier-induced cytotoxicity in human prostate cancer cells.</p>
<p>In this study, we demonstrated that Huaier-induced cytotoxicity and decreased cell mobility were at least partially mediated by downregulation of Lamin B1 and autophagic cell death in prostate cancer PC3 cells. The multiple mechanisms reported in our study contribute to the understanding of the complex anti-prostate cancer effects of Huaier. The present study provides a new theoretical basis for the clinical application of Huaier in prostate cancer.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgements</title>
<p>Not applicable.</p>
</ack>
<sec>
<title>Funding</title>
<p>The present study was financially supported by the National Natural Science Foundation of China (nos. 81403147 and 81402219), the Excellent Young Scientist Foundation of Beijing University of Chinese Medicine (no. 2015-JYB-XYQ-004), and the Outstanding Young Talent Foundation of the Organization Department of Beijing Municipal Party Committee (no. 2014000021469G221).</p>
</sec>
<sec>
<title>Availability of data and materials</title>
<p>All data generated or analyzed during this study are included in this published article.</p>
</sec>
<sec>
<title>Authors&#x0027; contributions</title>
<p>AY designed and performed the experiments, analyzed data and wrote the manuscript. YaZ, YW, XZ and YuZ analyzed data and revised the manuscript. PT and ZH supervised the study, designed experiments and revised the manuscript. All authors read and approved the manuscript and agree to be accountable for all aspects of the research in ensuring that the accuracy or integrity of any part of the work are appropriately investigated and resolved.</p>
</sec>
<sec>
<title>Ethics approval and consent to participate</title>
<p>Not applicable.</p>
</sec>
<sec>
<title>Consent for publication</title>
<p>Not applicable.</p>
</sec>
<sec>
<title>Competing interests</title>
<p>The authors declare that they have no competing interests.</p>
</sec>
<glossary>
<def-list>
<title>Abbreviations</title>
<def-item><term>TCM</term><def><p>Traditional Chinese Medicine</p></def></def-item>
<def-item><term>FBS</term><def><p>fetal bovine serum</p></def></def-item>
<def-item><term>OD</term><def><p>optical density</p></def></def-item>
<def-item><term>CCK-8</term><def><p>Cell Counting Kit-8</p></def></def-item>
<def-item><term>TEM</term><def><p>transmission electron microscopy</p></def></def-item>
</def-list>
</glossary>
<ref-list>
<title>References</title>
<ref id="b1-or-39-06-3055"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Denmeade</surname><given-names>SR</given-names></name><name><surname>Isaacs</surname><given-names>JT</given-names></name></person-group><article-title>A history of prostate cancer treatment</article-title><source>Nat Rev Cancer</source><volume>2</volume><fpage>389</fpage><lpage>396</lpage><year>2002</year><pub-id pub-id-type="doi">10.1038/nrc801</pub-id><pub-id pub-id-type="pmid">12044015</pub-id><pub-id pub-id-type="pmcid">4124639</pub-id></element-citation></ref>
<ref id="b2-or-39-06-3055"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trewartha</surname><given-names>D</given-names></name><name><surname>Carter</surname><given-names>K</given-names></name></person-group><article-title>Advances in prostate cancer treatment</article-title><source>Nat Rev Drug Discov</source><volume>12</volume><fpage>823</fpage><lpage>824</lpage><year>2013</year><pub-id pub-id-type="doi">10.1038/nrd4068</pub-id><pub-id pub-id-type="pmid">24172327</pub-id></element-citation></ref>
<ref id="b3-or-39-06-3055"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kelloff</surname><given-names>GJ</given-names></name></person-group><article-title>Perspectives on cancer chemoprevention research and drug development</article-title><source>Adv Cancer Res</source><volume>78</volume><fpage>199</fpage><lpage>334</lpage><year>2000</year><pub-id pub-id-type="doi">10.1016/S0065-230X(08)61026-X</pub-id><pub-id pub-id-type="pmid">10547671</pub-id></element-citation></ref>
<ref id="b4-or-39-06-3055"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hwang</surname><given-names>C</given-names></name></person-group><article-title>Overcoming docetaxel resistance in prostate cancer: A perspective review</article-title><source>Ther Adv Med Oncol</source><volume>4</volume><fpage>329</fpage><lpage>340</lpage><year>2012</year><pub-id pub-id-type="doi">10.1177/1758834012449685</pub-id><pub-id pub-id-type="pmid">23118808</pub-id><pub-id pub-id-type="pmcid">3481557</pub-id></element-citation></ref>
<ref id="b5-or-39-06-3055"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wallace</surname><given-names>TJ</given-names></name><name><surname>Torre</surname><given-names>T</given-names></name><name><surname>Grob</surname><given-names>M</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Avital</surname><given-names>I</given-names></name><name><surname>Br&#x00FC;cher</surname><given-names>B</given-names></name><name><surname>Stojadinovic</surname><given-names>A</given-names></name><name><surname>Man</surname><given-names>YG</given-names></name></person-group><article-title>Current approaches, challenges and future directions for monitoring treatment response in prostate cancer</article-title><source>J Cancer</source><volume>5</volume><fpage>3</fpage><lpage>24</lpage><year>2014</year><pub-id pub-id-type="doi">10.7150/jca.7709</pub-id><pub-id pub-id-type="pmid">24396494</pub-id><pub-id pub-id-type="pmcid">3881217</pub-id></element-citation></ref>
<ref id="b6-or-39-06-3055"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>CY</given-names></name><name><surname>Bai</surname><given-names>XY</given-names></name><name><surname>Wang</surname><given-names>CH</given-names></name></person-group><article-title>Traditional Chinese medicine: A treasured natural resource of anticancer drug research and development</article-title><source>Am J Chin Med</source><volume>42</volume><fpage>543</fpage><lpage>559</lpage><year>2014</year><pub-id pub-id-type="doi">10.1142/S0192415X14500359</pub-id><pub-id pub-id-type="pmid">24871650</pub-id></element-citation></ref>
<ref id="b7-or-39-06-3055"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>P</given-names></name><name><surname>Zhang</surname><given-names>K</given-names></name><name><surname>Lin</surname><given-names>X</given-names></name></person-group><article-title>Antitumor effects of traditional Chinese medicine targeting the cellular apoptotic pathway</article-title><source>Drug Des Devel Ther</source><volume>9</volume><fpage>2735</fpage><lpage>2744</lpage><year>2015</year><pub-id pub-id-type="pmid">26056434</pub-id><pub-id pub-id-type="pmcid">4445699</pub-id></element-citation></ref>
<ref id="b8-or-39-06-3055"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>Z</given-names></name><name><surname>Lai</surname><given-names>Z</given-names></name><name><surname>Lin</surname><given-names>J</given-names></name></person-group><article-title>Anticancer properties of traditional Chinese medicine</article-title><source>Comb Chem High Throughput Screen</source><volume>20</volume><fpage>423</fpage><lpage>429</lpage><year>2017</year><pub-id pub-id-type="doi">10.2174/1386207320666170116141818</pub-id><pub-id pub-id-type="pmid">28093974</pub-id></element-citation></ref>
<ref id="b9-or-39-06-3055"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>Q</given-names></name></person-group><article-title>The anticancer effect of Huaier (Review)</article-title><source>Oncol Rep</source><volume>34</volume><fpage>12</fpage><lpage>21</lpage><year>2015</year><pub-id pub-id-type="doi">10.3892/or.2015.3950</pub-id><pub-id pub-id-type="pmid">25955759</pub-id></element-citation></ref>
<ref id="b10-or-39-06-3055"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>Z</given-names></name><name><surname>Yang</surname><given-names>A</given-names></name><name><surname>Su</surname><given-names>G</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Chai</surname><given-names>X</given-names></name><name><surname>Tu</surname><given-names>P</given-names></name></person-group><article-title>Huaier restrains proliferative and invasive potential of human hepatoma SKHEP-1 cells partially through decreased Lamin B1 and elevated NOV</article-title><source>Sci Rep</source><volume>6</volume><fpage>31298</fpage><year>2016</year><pub-id pub-id-type="doi">10.1038/srep31298</pub-id><pub-id pub-id-type="pmid">27503760</pub-id><pub-id pub-id-type="pmcid">4977525</pub-id></element-citation></ref>
<ref id="b11-or-39-06-3055"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Qi</surname><given-names>W</given-names></name><name><surname>Song</surname><given-names>X</given-names></name><name><surname>Lv</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>Q</given-names></name></person-group><article-title>Huaier extract suppresses breast cancer via regulating tumor-associated macrophages</article-title><source>Sci Rep</source><volume>6</volume><fpage>20049</fpage><year>2016</year><pub-id pub-id-type="doi">10.1038/srep20049</pub-id><pub-id pub-id-type="pmid">26831282</pub-id><pub-id pub-id-type="pmcid">4735520</pub-id></element-citation></ref>
<ref id="b12-or-39-06-3055"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>X</given-names></name><name><surname>Lyu</surname><given-names>T</given-names></name><name><surname>Jia</surname><given-names>N</given-names></name><name><surname>Yu</surname><given-names>Y</given-names></name><name><surname>Hua</surname><given-names>K</given-names></name><name><surname>Feng</surname><given-names>W</given-names></name></person-group><article-title>Huaier aqueous extract inhibits ovarian cancer cell motility via the AKT/GSK3&#x03B2;/&#x03B2;-catenin pathway</article-title><source>PLoS One</source><volume>8</volume><fpage>e63731</fpage><year>2013</year><pub-id pub-id-type="doi">10.1371/journal.pone.0063731</pub-id><pub-id pub-id-type="pmid">23667667</pub-id><pub-id pub-id-type="pmcid">3648479</pub-id></element-citation></ref>
<ref id="b13-or-39-06-3055"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>N</given-names></name><name><surname>Huo</surname><given-names>Q</given-names></name><name><surname>Yang</surname><given-names>Q</given-names></name></person-group><article-title>Anti-angiogenic and antitumor activities of Huaier aqueous extract</article-title><source>Oncol Rep</source><volume>28</volume><fpage>1167</fpage><lpage>1175</lpage><year>2012</year><pub-id pub-id-type="doi">10.3892/or.2012.1961</pub-id><pub-id pub-id-type="pmid">22895629</pub-id><pub-id pub-id-type="pmcid">3583466</pub-id></element-citation></ref>
<ref id="b14-or-39-06-3055"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>T</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Lu</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Kong</surname><given-names>D</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Kong</surname><given-names>Q</given-names></name><name><surname>Ning</surname><given-names>Y</given-names></name><name><surname>Lu</surname><given-names>Z</given-names></name></person-group><article-title>Huaier suppresses proliferation and induces apoptosis in human pulmonary cancer cells via upregulation of miR-26b-5p</article-title><source>FEBS Lett</source><volume>588</volume><fpage>2107</fpage><lpage>2114</lpage><year>2014</year><pub-id pub-id-type="doi">10.1016/j.febslet.2014.04.044</pub-id><pub-id pub-id-type="pmid">24815696</pub-id></element-citation></ref>
<ref id="b15-or-39-06-3055"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>AL</given-names></name><name><surname>Hu</surname><given-names>ZD</given-names></name><name><surname>Tu</surname><given-names>PF</given-names></name></person-group><article-title>Research progress on anti-tumor effect of Huaier</article-title><source>Zhongguo Zhong Yao Za Zhi</source><volume>40</volume><fpage>4805</fpage><lpage>4810</lpage><year>2015</year><pub-id pub-id-type="pmid">27245026</pub-id></element-citation></ref>
<ref id="b16-or-39-06-3055"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>N</given-names></name><name><surname>Huo</surname><given-names>Q</given-names></name><name><surname>Sun</surname><given-names>M</given-names></name><name><surname>Lv</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>Q</given-names></name></person-group><article-title>Huaier aqueous extract suppresses human breast cancer cell proliferation through inhibition of estrogen receptor &#x03B1; signaling</article-title><source>Int J Oncol</source><volume>43</volume><fpage>321</fpage><lpage>328</lpage><year>2013</year><pub-id pub-id-type="doi">10.3892/ijo.2013.1947</pub-id><pub-id pub-id-type="pmid">23686317</pub-id></element-citation></ref>
<ref id="b17-or-39-06-3055"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Yin</surname><given-names>A</given-names></name><name><surname>Wei</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>Q</given-names></name><name><surname>Kong</surname><given-names>B</given-names></name></person-group><article-title>Huaier aqueous extract inhibits cervical cancer cell proliferation via JNK/p38 pathway</article-title><source>Int J Oncol</source><volume>47</volume><fpage>1054</fpage><lpage>1060</lpage><year>2015</year><pub-id pub-id-type="doi">10.3892/ijo.2015.3094</pub-id><pub-id pub-id-type="pmid">26201539</pub-id></element-citation></ref>
<ref id="b18-or-39-06-3055"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>A</given-names></name><name><surname>Fan</surname><given-names>H</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Zha</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Hu</surname><given-names>Z</given-names></name><name><surname>Tu</surname><given-names>P</given-names></name></person-group><article-title>Huaier aqueous extract inhibits proliferation and metastasis of tuberous sclerosis complex cell models through downregulation of JAK2/STAT3 and MAPK signaling pathways</article-title><source>Oncol Rep</source><volume>36</volume><fpage>1491</fpage><lpage>1498</lpage><year>2016</year><pub-id pub-id-type="doi">10.3892/or.2016.4969</pub-id><pub-id pub-id-type="pmid">27461043</pub-id></element-citation></ref>
<ref id="b19-or-39-06-3055"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coradeghini</surname><given-names>R</given-names></name><name><surname>Barboro</surname><given-names>P</given-names></name><name><surname>Rubagotti</surname><given-names>A</given-names></name><name><surname>Boccardo</surname><given-names>F</given-names></name><name><surname>Parodi</surname><given-names>S</given-names></name><name><surname>Carmignani</surname><given-names>G</given-names></name><name><surname>D&#x0027;Arrigo</surname><given-names>C</given-names></name><name><surname>Patrone</surname><given-names>E</given-names></name><name><surname>Balbi</surname><given-names>C</given-names></name></person-group><article-title>Differential expression of nuclear lamins in normal and cancerous prostate tissues</article-title><source>Oncol Rep</source><volume>15</volume><fpage>609</fpage><lpage>613</lpage><year>2006</year><pub-id pub-id-type="pmid">16465420</pub-id></element-citation></ref>
<ref id="b20-or-39-06-3055"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klionsky</surname><given-names>DJ</given-names></name></person-group><article-title>Autophagy: From phenomenology to molecular understanding in less than a decade</article-title><source>Nat Rev Mol Cell Biol</source><volume>8</volume><fpage>931</fpage><lpage>937</lpage><year>2007</year><pub-id pub-id-type="doi">10.1038/nrm2245</pub-id><pub-id pub-id-type="pmid">17712358</pub-id></element-citation></ref>
<ref id="b21-or-39-06-3055"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>F</given-names></name><name><surname>Chen</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Goto</surname><given-names>J</given-names></name><name><surname>Kwiatkowski</surname><given-names>DJ</given-names></name><name><surname>Wdzieczak-Bakala</surname><given-names>J</given-names></name><name><surname>Tu</surname><given-names>P</given-names></name><etal/></person-group><article-title>Brain-expressed X-linked 2 is pivotal for hyperactive mechanistic target of rapamycin (mTOR)-mediated tumorigenesis</article-title><source>J Biol Chem</source><volume>290</volume><fpage>25756</fpage><lpage>25765</lpage><year>2015</year><pub-id pub-id-type="doi">10.1074/jbc.M115.665208</pub-id><pub-id pub-id-type="pmid">26296882</pub-id><pub-id pub-id-type="pmcid">4646217</pub-id></element-citation></ref>
<ref id="b22-or-39-06-3055"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yl&#x00E4;-Anttila</surname><given-names>P</given-names></name><name><surname>Vihinen</surname><given-names>H</given-names></name><name><surname>Jokitalo</surname><given-names>E</given-names></name><name><surname>Eskelinen</surname><given-names>EL</given-names></name></person-group><article-title>Monitoring autophagy by electron microscopy in Mammalian cells</article-title><source>Methods Enzymol</source><volume>452</volume><fpage>143</fpage><lpage>164</lpage><year>2009</year><pub-id pub-id-type="doi">10.1016/S0076-6879(08)03610-0</pub-id><pub-id pub-id-type="pmid">19200881</pub-id></element-citation></ref>
<ref id="b23-or-39-06-3055"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dittmer</surname><given-names>TA</given-names></name><name><surname>Misteli</surname><given-names>T</given-names></name></person-group><article-title>The lamin protein family</article-title><source>Genome Biol</source><volume>12</volume><fpage>222</fpage><year>2011</year><pub-id pub-id-type="doi">10.1186/gb-2011-12-5-222</pub-id><pub-id pub-id-type="pmid">21639948</pub-id><pub-id pub-id-type="pmcid">3219962</pub-id></element-citation></ref>
<ref id="b24-or-39-06-3055"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>S</given-names></name><name><surname>Xu</surname><given-names>MZ</given-names></name><name><surname>Poon</surname><given-names>RT</given-names></name><name><surname>Day</surname><given-names>PJ</given-names></name><name><surname>Luk</surname><given-names>JM</given-names></name></person-group><article-title>Circulating Lamin B1 (LMNB1) biomarker detects early stages of liver cancer in patients</article-title><source>J Proteome Res</source><volume>9</volume><fpage>70</fpage><lpage>78</lpage><year>2010</year><pub-id pub-id-type="doi">10.1021/pr9002118</pub-id><pub-id pub-id-type="pmid">19522540</pub-id></element-citation></ref>
<ref id="b25-or-39-06-3055"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Du</surname><given-names>Y</given-names></name><name><surname>Kong</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Jia</surname><given-names>Z</given-names></name><name><surname>Cui</surname><given-names>J</given-names></name><name><surname>Gao</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>G</given-names></name><name><surname>Xie</surname><given-names>K</given-names></name></person-group><article-title>Lamin B1 is a novel therapeutic target of betulinic acid in pancreatic cancer</article-title><source>Clin Cancer Res</source><volume>19</volume><fpage>4651</fpage><lpage>4661</lpage><year>2013</year><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-12-3630</pub-id><pub-id pub-id-type="pmid">23857605</pub-id><pub-id pub-id-type="pmcid">3800003</pub-id></element-citation></ref>
<ref id="b26-or-39-06-3055"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsujimoto</surname><given-names>Y</given-names></name><name><surname>Shimizu</surname><given-names>S</given-names></name></person-group><article-title>Another way to die: Autophagic programmed cell death</article-title><source>Cell Death Differ</source><volume>12</volume><supplement>Suppl 2</supplement><fpage>S1528</fpage><lpage>S1534</lpage><year>2005</year><pub-id pub-id-type="doi">10.1038/sj.cdd.4401777</pub-id></element-citation></ref>
<ref id="b27-or-39-06-3055"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fulda</surname><given-names>S</given-names></name><name><surname>K&#x00F6;gel</surname><given-names>D</given-names></name></person-group><article-title>Cell death by autophagy: Emerging molecular mechanisms and implications for cancer therapy</article-title><source>Oncogene</source><volume>34</volume><fpage>5105</fpage><lpage>5113</lpage><year>2015</year><pub-id pub-id-type="doi">10.1038/onc.2014.458</pub-id><pub-id pub-id-type="pmid">25619832</pub-id></element-citation></ref>
<ref id="b28-or-39-06-3055"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petibone</surname><given-names>DM</given-names></name><name><surname>Majeed</surname><given-names>W</given-names></name><name><surname>Casciano</surname><given-names>DA</given-names></name></person-group><article-title>Autophagy function and its relationship to pathology, clinical applications, drug metabolism and toxicity</article-title><source>J Appl Toxicol</source><volume>37</volume><fpage>23</fpage><lpage>37</lpage><year>2017</year><pub-id pub-id-type="doi">10.1002/jat.3393</pub-id><pub-id pub-id-type="pmid">27682190</pub-id></element-citation></ref>
<ref id="b29-or-39-06-3055"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dunn</surname><given-names>WA</given-names><suffix>Jr</suffix></name></person-group><article-title>Studies on the mechanisms of autophagy: Formation of the autophagic vacuole</article-title><source>J Cell Biol</source><volume>110</volume><fpage>1923</fpage><lpage>1933</lpage><year>1990</year><pub-id pub-id-type="doi">10.1083/jcb.110.6.1923</pub-id><pub-id pub-id-type="pmid">2351689</pub-id><pub-id pub-id-type="pmcid">2116114</pub-id></element-citation></ref>
<ref id="b30-or-39-06-3055"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>AD</given-names></name><name><surname>Kang</surname><given-names>KA</given-names></name><name><surname>Kim</surname><given-names>HS</given-names></name><name><surname>Kim</surname><given-names>DH</given-names></name><name><surname>Choi</surname><given-names>YH</given-names></name><name><surname>Lee</surname><given-names>SJ</given-names></name><name><surname>Kim</surname><given-names>HS</given-names></name><name><surname>Hyun</surname><given-names>JW</given-names></name></person-group><article-title>A ginseng metabolite, compound K, induces autophagy and apoptosis via generation of reactive oxygen species and activation of JNK in human colon cancer cells</article-title><source>Cell Death Dis</source><volume>4</volume><fpage>e750</fpage><year>2013</year><pub-id pub-id-type="doi">10.1038/cddis.2013.273</pub-id><pub-id pub-id-type="pmid">23907464</pub-id><pub-id pub-id-type="pmcid">3763435</pub-id></element-citation></ref>
<ref id="b31-or-39-06-3055"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noda</surname><given-names>NN</given-names></name><name><surname>Inagaki</surname><given-names>F</given-names></name></person-group><article-title>Mechanisms of autophagy</article-title><source>Annu Rev Biophys</source><volume>44</volume><fpage>101</fpage><lpage>122</lpage><year>2015</year><pub-id pub-id-type="doi">10.1146/annurev-biophys-060414-034248</pub-id><pub-id pub-id-type="pmid">25747593</pub-id></element-citation></ref>
<ref id="b32-or-39-06-3055"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Fang</surname><given-names>S</given-names></name><name><surname>Su</surname><given-names>J</given-names></name><name><surname>Jiang</surname><given-names>J</given-names></name><name><surname>Liang</surname><given-names>B</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>B</given-names></name><name><surname>Zang</surname><given-names>N</given-names></name><name><surname>Ho</surname><given-names>W</given-names></name><etal/></person-group><article-title>Downregulation of autophagy-related gene ATG5 and GABARAP expression by IFN-&#x03BB;1 contributes to its anti-HCV activity in human hepatoma cells</article-title><source>Antiviral Res</source><volume>140</volume><fpage>83</fpage><lpage>94</lpage><year>2017</year><pub-id pub-id-type="doi">10.1016/j.antiviral.2017.01.016</pub-id><pub-id pub-id-type="pmid">28131804</pub-id></element-citation></ref>
<ref id="b33-or-39-06-3055"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>K</given-names></name><name><surname>Fu</surname><given-names>W</given-names></name><name><surname>Tang</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Hou</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>R</given-names></name><name><surname>Lu</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><etal/></person-group><article-title>PTK2-mediated degradation of ATG3 impedes cancer cells susceptible to DNA damage treatment</article-title><source>Autophagy</source><volume>13</volume><fpage>579</fpage><lpage>591</lpage><year>2017</year><pub-id pub-id-type="doi">10.1080/15548627.2016.1272742</pub-id><pub-id pub-id-type="pmid">28103122</pub-id><pub-id pub-id-type="pmcid">5361600</pub-id></element-citation></ref>
<ref id="b34-or-39-06-3055"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanida</surname><given-names>I</given-names></name><name><surname>Ueno</surname><given-names>T</given-names></name><name><surname>Kominami</surname><given-names>E</given-names></name></person-group><article-title>LC3 and autophagy</article-title><source>Methods Mol Biol</source><volume>445</volume><fpage>77</fpage><lpage>88</lpage><year>2008</year><pub-id pub-id-type="doi">10.1007/978-1-59745-157-4_4</pub-id><pub-id pub-id-type="pmid">18425443</pub-id></element-citation></ref>
<ref id="b35-or-39-06-3055"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mizushima</surname><given-names>N</given-names></name><name><surname>Yoshimori</surname><given-names>T</given-names></name></person-group><article-title>How to interpret LC3 immunoblotting</article-title><source>Autophagy</source><volume>3</volume><fpage>542</fpage><lpage>545</lpage><year>2007</year><pub-id pub-id-type="doi">10.4161/auto.4600</pub-id><pub-id pub-id-type="pmid">17611390</pub-id></element-citation></ref>
<ref id="b36-or-39-06-3055"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>R</given-names></name><name><surname>Zeh</surname><given-names>HJ</given-names></name><name><surname>Lotze</surname><given-names>MT</given-names></name><name><surname>Tang</surname><given-names>D</given-names></name></person-group><article-title>The Beclin 1 network regulates autophagy and apoptosis</article-title><source>Cell Death Differ</source><volume>18</volume><fpage>571</fpage><lpage>580</lpage><year>2011</year><pub-id pub-id-type="doi">10.1038/cdd.2010.191</pub-id><pub-id pub-id-type="pmid">21311563</pub-id><pub-id pub-id-type="pmcid">3131912</pub-id></element-citation></ref>
<ref id="b37-or-39-06-3055"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanahan</surname><given-names>D</given-names></name><name><surname>Weinberg</surname><given-names>RA</given-names></name></person-group><article-title>Hallmarks of cancer: The next generation</article-title><source>Cell</source><volume>144</volume><fpage>646</fpage><lpage>674</lpage><year>2011</year><pub-id pub-id-type="doi">10.1016/j.cell.2011.02.013</pub-id><pub-id pub-id-type="pmid">21376230</pub-id></element-citation></ref>
<ref id="b38-or-39-06-3055"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valastyan</surname><given-names>S</given-names></name><name><surname>Weinberg</surname><given-names>RA</given-names></name></person-group><article-title>Tumor metastasis: Molecular insights and evolving paradigms</article-title><source>Cell</source><volume>147</volume><fpage>275</fpage><lpage>292</lpage><year>2011</year><pub-id pub-id-type="doi">10.1016/j.cell.2011.09.024</pub-id><pub-id pub-id-type="pmid">22000009</pub-id><pub-id pub-id-type="pmcid">3261217</pub-id></element-citation></ref>
<ref id="b39-or-39-06-3055"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mehlen</surname><given-names>P</given-names></name><name><surname>Puisieux</surname><given-names>A</given-names></name></person-group><article-title>Metastasis: A question of life or death</article-title><source>Nat Rev Cancer</source><volume>6</volume><fpage>449</fpage><lpage>458</lpage><year>2006</year><pub-id pub-id-type="doi">10.1038/nrc1886</pub-id><pub-id pub-id-type="pmid">16723991</pub-id></element-citation></ref>
<ref id="b40-or-39-06-3055"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bubendorf</surname><given-names>L</given-names></name><name><surname>Sch&#x00F6;pfer</surname><given-names>A</given-names></name><name><surname>Wagner</surname><given-names>U</given-names></name><name><surname>Sauter</surname><given-names>G</given-names></name><name><surname>Moch</surname><given-names>H</given-names></name><name><surname>Willi</surname><given-names>N</given-names></name><name><surname>Gasser</surname><given-names>TC</given-names></name><name><surname>Mihatsch</surname><given-names>MJ</given-names></name></person-group><article-title>Metastatic patterns of prostate cancer: An autopsy study of 1,589 patients</article-title><source>Hum Pathol</source><volume>31</volume><fpage>578</fpage><lpage>583</lpage><year>2000</year><pub-id pub-id-type="doi">10.1053/hp.2000.6698</pub-id><pub-id pub-id-type="pmid">10836297</pub-id></element-citation></ref>
<ref id="b41-or-39-06-3055"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>JC</given-names></name><name><surname>Eisenberger</surname><given-names>MA</given-names></name></person-group><article-title>Advances in the treatment of metastatic prostate cancer</article-title><source>Mayo Clin Proc</source><volume>90</volume><fpage>1719</fpage><lpage>1733</lpage><year>2015</year><pub-id pub-id-type="doi">10.1016/j.mayocp.2015.10.010</pub-id><pub-id pub-id-type="pmid">26653301</pub-id></element-citation></ref>
<ref id="b42-or-39-06-3055"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harborth</surname><given-names>J</given-names></name><name><surname>Elbashir</surname><given-names>SM</given-names></name><name><surname>Bechert</surname><given-names>K</given-names></name><name><surname>Tuschl</surname><given-names>T</given-names></name><name><surname>Weber</surname><given-names>K</given-names></name></person-group><article-title>Identification of essential genes in cultured mammalian cells using small interfering RNAs</article-title><source>J Cell Sci</source><volume>114</volume><fpage>4557</fpage><lpage>4565</lpage><year>2001</year><pub-id pub-id-type="pmid">11792820</pub-id></element-citation></ref>
<ref id="b43-or-39-06-3055"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levine</surname><given-names>B</given-names></name><name><surname>Klionsky</surname><given-names>DJ</given-names></name></person-group><article-title>Development by self-digestion: Molecular mechanisms and biological functions of autophagy</article-title><source>Dev Cell</source><volume>6</volume><fpage>463</fpage><lpage>477</lpage><year>2004</year><pub-id pub-id-type="doi">10.1016/S1534-5807(04)00099-1</pub-id><pub-id pub-id-type="pmid">15068787</pub-id></element-citation></ref>
<ref id="b44-or-39-06-3055"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gozuacik</surname><given-names>D</given-names></name><name><surname>Kimchi</surname><given-names>A</given-names></name></person-group><article-title>Autophagy as a cell death and tumor suppressor mechanism</article-title><source>Oncogene</source><volume>23</volume><fpage>2891</fpage><lpage>2906</lpage><year>2004</year><pub-id pub-id-type="doi">10.1038/sj.onc.1207521</pub-id><pub-id pub-id-type="pmid">15077152</pub-id></element-citation></ref>
<ref id="b45-or-39-06-3055"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>WL</given-names></name><name><surname>Perillo</surname><given-names>W</given-names></name><name><surname>Liou</surname><given-names>D</given-names></name><name><surname>Marambaud</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>P</given-names></name></person-group><article-title>AMPK inhibitor compound C suppresses cell proliferation by induction of apoptosis and autophagy in human colorectal cancer cells</article-title><source>J Surg Oncol</source><volume>106</volume><fpage>680</fpage><lpage>688</lpage><year>2012</year><pub-id pub-id-type="doi">10.1002/jso.23184</pub-id><pub-id pub-id-type="pmid">22674626</pub-id></element-citation></ref>
<ref id="b46-or-39-06-3055"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>Z</given-names></name><name><surname>Xie</surname><given-names>F</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Liang</surname><given-names>Z</given-names></name><name><surname>Xu</surname><given-names>W</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Qu</surname><given-names>LH</given-names></name></person-group><article-title>Oridonin induces autophagy via inhibition of glucose metabolism in p53-mutated colorectal cancer cells</article-title><source>Cell Death Dis</source><volume>8</volume><fpage>e2633</fpage><year>2017</year><pub-id pub-id-type="doi">10.1038/cddis.2017.35</pub-id><pub-id pub-id-type="pmid">28230866</pub-id><pub-id pub-id-type="pmcid">5386482</pub-id></element-citation></ref>
<ref id="b47-or-39-06-3055"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>ZJ</given-names></name><name><surname>Chee</surname><given-names>CE</given-names></name><name><surname>Huang</surname><given-names>S</given-names></name><name><surname>Sinicrope</surname><given-names>FA</given-names></name></person-group><article-title>The role of autophagy in cancer: Therapeutic implications</article-title><source>Mol Cancer Ther</source><volume>10</volume><fpage>1533</fpage><lpage>1541</lpage><year>2011</year><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-11-0047</pub-id><pub-id pub-id-type="pmid">21878654</pub-id><pub-id pub-id-type="pmcid">3170456</pub-id></element-citation></ref>
<ref id="b48-or-39-06-3055"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Qi</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>N</given-names></name><name><surname>Dong</surname><given-names>L</given-names></name><name><surname>Sun</surname><given-names>M</given-names></name><name><surname>Cun</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Lv</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>Q</given-names></name></person-group><article-title>Huaier extract induces autophagic cell death by inhibiting the mTOR/S6K pathway in breast cancer cells</article-title><source>PLoS One</source><volume>10</volume><fpage>e0131771</fpage><year>2015</year><pub-id pub-id-type="doi">10.1371/journal.pone.0131771</pub-id><pub-id pub-id-type="pmid">26134510</pub-id><pub-id pub-id-type="pmcid">4489895</pub-id></element-citation></ref>
<ref id="b49-or-39-06-3055"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qi</surname><given-names>W</given-names></name><name><surname>Sun</surname><given-names>M</given-names></name><name><surname>Kong</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Lv</surname><given-names>S</given-names></name><name><surname>Ding</surname><given-names>X</given-names></name><name><surname>Gao</surname><given-names>S</given-names></name><name><surname>Cun</surname><given-names>J</given-names></name><name><surname>Cai</surname><given-names>C</given-names></name><etal/></person-group><article-title>Huaier extract synergizes with tamoxifen to induce autophagy and apoptosis in ER-positive breast cancer cells</article-title><source>Oncotarget</source><volume>7</volume><fpage>26003</fpage><lpage>26015</lpage><year>2016</year><pub-id pub-id-type="doi">10.18632/oncotarget.8303</pub-id><pub-id pub-id-type="pmid">27027343</pub-id><pub-id pub-id-type="pmcid">5041960</pub-id></element-citation></ref>
</ref-list>
</back>
<floats-group>
<fig id="f1-or-39-06-3055" position="float">
<label>Figure 1.</label>
<caption><p>Huaier suppresses the proliferative and metastatic potential of human prostate cancer PC3 cells. (A) PC3 cells were treated with Huaier extract (0&#x2013;8 mg/ml) for 24 and 48 h. Cell viability was measured by the CCK-8 assay. &#x002A;&#x002A;P&#x003C;0.01, <sup>##</sup>P&#x003C;0.01, <sup>###</sup>P&#x003C;0.001. (B) PC3 cells treated with Huaier extract (4 mg/ml) were subjected to the scratch assay and observed at 0 and 24 h. Left panel, representative images are presented (magnification, &#x00D7;100); right panel, quantitative data. &#x002A;P&#x003C;0.05. (C) PC3 cells treated with Huaier extract (4 mg/ml) for 36 h were subjected to Transwell assay. Left panel, representative images are presented (magnification, &#x00D7;200); right panel, quantitative data. &#x002A;&#x002A;P&#x003C;0.01.</p></caption>
<graphic xlink:href="OR-39-06-3055-g00.tif"/>
</fig>
<fig id="f2-or-39-06-3055" position="float">
<label>Figure 2.</label>
<caption><p>Huaier downregulates Lamin B1 expression in human prostate cancer PC3 cells. Total RNA (A) or cell lysates (B) collected from PC3 cells treated with Huaier extract (0&#x2013;8 mg/ml) for 48 h were subjected to quantitative real-time PCR and immunoblotting, respectively. &#x002A;P&#x003C;0.05, &#x002A;&#x002A;&#x002A;P&#x003C;0.001.</p></caption>
<graphic xlink:href="OR-39-06-3055-g01.tif"/>
</fig>
<fig id="f3-or-39-06-3055" position="float">
<label>Figure 3.</label>
<caption><p>Lamin B1 is required for the proliferation and metastatic potential of PC3 cells. (A) PC3 cells were transfected with siRNAs against Lamin B1 for 48 h and total protein lysates were harvested for immunoblotting. (B) The proliferation of PC3 cells transfected with Lamin B1 siRNAs or negative control siRNAs was assessed by CCK-8 assay. (C) PC3 cells transfected with Lamin B1 siRNAs or negative control siRNAs were subjected to the scratch assay and observed at 0 and 24 h. Left panel, representative images are presented (magnification, &#x00D7;100); right panel, quantitative data. (D) PC3 cells transfected with Lamin B1 siRNAs or negative control siRNAs were subjected to Transwell assay. Left panel, representative images are presented (magnification, &#x00D7;200); right panel, quantitative data. &#x002A;&#x002A;&#x002A;P&#x003C;0.001.</p></caption>
<graphic xlink:href="OR-39-06-3055-g02.tif"/>
</fig>
<fig id="f4-or-39-06-3055" position="float">
<label>Figure 4.</label>
<caption><p>Depletion of Lamin B1 compromises the inhibitory effect of Huaier on the proliferative and metastatic potential of PC3 cells. (A-C) PC3 cells transfected with Lamin B1 siRNAs or negative control siRNAs were treated with or without Huaier extract. (A) Cell viability of the indicated cells was measured by CCK-8 assay. (B) The indicated cells were subjected to the scratch assay and observed at 0 and 24 h. Left panel, representative images are presented (magnification, &#x00D7;100); right panel, quantitative data. (C) The indicated cells were subjected to Transwell assay. Left panel, representative images are presented (magnification, &#x00D7;200); right panel, quantitative data. &#x002A;&#x002A;P&#x003C;0.01, &#x002A;&#x002A;&#x002A;P&#x003C;0.001.</p></caption>
<graphic xlink:href="OR-39-06-3055-g03.tif"/>
</fig>
<fig id="f5-or-39-06-3055" position="float">
<label>Figure 5.</label>
<caption><p>Huaier induces autophagy in PC3 cells. (A) Transmission electron microscopy (TEM) analysis of PC3 cells treated with Huaier extract (8 mg/ml) for 48 h. White arrows indicated autolysosomes/autophagosomes. Scale bar, 500 nm. N, nucleus. (B) PC3 cells treated with Huaier extract (8 mg/ml) for 0, 12, 24 and 48 h were stained with acridine orange (10 &#x00B5;g/ml), and observed under a fluorescence microscopy. Scale bar, 100 &#x00B5;m. (C and D) Total cell lysates harvested from PC3 cells treated with Huaier extract at the concentrations of 0, 4 and 8 mg/ml for 48 h (C) or treated with 8 mg/ml Huaier extract for the indicated times (0, 12, 24 and 48 h) (D) were subjected to immunoblotting for detection of Atg3, Atg5, Beclin-1 and LC3. (E) PC3 cells treated with 8 mg/ml Huaier extract for 48 h were stained with anti-LC3 antibody. The LC3 puncta (green) were observed through immunofluorescence. Nuclei were stained with DAPI (blue). Representative images are presented. Scale bar, 20 &#x00B5;m.</p></caption>
<graphic xlink:href="OR-39-06-3055-g04.tif"/>
</fig>
<fig id="f6-or-39-06-3055" position="float">
<label>Figure 6.</label>
<caption><p>Inhibition of autophagy attenuates Huaier-induced cytotoxicity in PC3 cells. (A) PC3 cells were treated with Huaier extract (0&#x2013;8 mg/ml) for 48 h in the absence or presence of 3-MA (2 mM). (B) PC3 cells were treated with Huaier extract (0&#x2013;8 mg/ml) for 48 h in the absence or presence of bafilomycin A1 (200 nM). (C) PC3 cells transfected with Atg5 siRNAs or negative control siRNAs were treated with Huaier extract (0&#x2013;8 mg/ml) for 48 h, and the protein level of Atg5 was examined by immunoblotting. (D) PC3 cells transfected with Beclin-1 siRNAs or negative control siRNAs were treated with Huaier extract (0&#x2013;8 mg/ml) for 48 h, and the protein level of Beclin-1 was examined by immunoblotting. The cell viability was measured with the CCK-8 assay. &#x002A;P&#x003C;0.05, &#x002A;&#x002A;P&#x003C;0.01, &#x002A;&#x002A;&#x002A;P&#x003C;0.001.</p></caption>
<graphic xlink:href="OR-39-06-3055-g05.tif"/>
</fig>
</floats-group>
</article>